Bicalutamide

Bicalutamide

Catalog Number:
L002369305APE
Mfr. No.:
APE-A5065
Price:
$188
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Bicalutamide is an active non-steroidal androgen receptor antagonist with IC50 value of 160 nM.[1] The androgen receptor (AR) is a type of nuclear receptor. It is activated by binding of either of dihydrotestosterone or the androgenic hormones testosterone. Then, it will translocate into the nucleus as DNA-binding transcription factor which regulates gene expression. Androgen is critical for the maintenance and development of the male sexual phenotype through related gene. The androgen receptor (AR) is also related to the core mechanism of castration-resistant prostate cancer.[1]Bicalutamide inhibits growth in prostate cancer cells (VCaP cells) which overexpress androgen receptor by directly binding to AR then mediates androgen-mediated gene transcription with IC50 value of 160 nM. Bicalutamide directly binds to androgen receptor with Ki value of 12.5μM. In prostate cancer cells, bicalutamide impairs DNA binding and nuclear localization. Bicalutamide and MDV3100 significantly inhibited R1881-induced VP16-AR–mediated transcription in HepG2 cells with an IC50 value of 0.2 μM.[1] Bicalutamide has been an molecular template for designing selective androgen receptor antagonist used to the treatment of prostate cancer cells.[2] Bicalutamide also induces cell death by a different pathway which is independent of mitochondrial membrane potential changes and Bcl-2 action.[1]Bicalutamide significantly inhibited AR then decrease the tumor growth in murine xenograft models, male immunodeficient mice which harbors LNCaP/AR-luc xenograft tumors.[1]

          [1]. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L et al: ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012, 72(6):1494-1503.
          [2]. Yin D, He Y, Perera MA, Hong SS, Marhefka C, Stourman N, Kirkovsky L, Miller DD, Dalton JT: Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol 2003, 63(1):211-223.

      • Properties
        • Categories
          Androgen receptor antagonist
          Alternative Name
          N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
          CAS Number
          90357-06-5
          Molecular Formula
          C18H14F4N2O4S
          Molecular Weight
          430.37
          Appearance
          A solid
          Purity
          98.00%
          Solubility
          ≥21.5 mg/mL in DMSO; insoluble in H2O; ≥4.3 mg/mL in EtOH with ultrasonic
          Storage
          Store at -20°C
          SMILES
          CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O

          * For Research Use Only

      • Reference
        • 1. Nair Lopes, Mariana Brütt Pacheco, et al. "Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer." Biomedicines. 2021 Aug 7;9(8):976. PMID:34440180
          2. Ben Liu, Meng Zhou, et al. "Interrogation of gender disparity uncovers androgen receptor as the transcriptional activator for oncogenic miR-125b in gastric cancer." Cell Death Dis. 2021 May 4;12(5):441. PMID:33947843
          3. Bogner J, Zolghadr K, et al. "The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators." J Steroid Biochem Mol Biol. 2016 May 9. PMID:27174722

    We Also Recommend

    GDC-0879

    $292

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.